Published in Bone on September 24, 2012
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol (2013) 1.23
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Osteocyte-driven bone remodeling. Calcif Tissue Int (2013) 1.08
The rachitic tooth. Endocr Rev (2013) 0.96
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95
Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology (2014) 0.92
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem (2013) 0.88
The osteocyte: key player in regulating bone turnover. RMD Open (2015) 0.83
The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2014) 0.82
Parathyroid Hormone Induces Bone Cell Motility and Loss of Mature Osteocyte Phenotype through L-Calcium Channel Dependent and Independent Mechanisms. PLoS One (2015) 0.82
Intermittently administered parathyroid hormone [1-34] promotes tendon-bone healing in a rat model. Int J Mol Sci (2014) 0.81
Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol (2016) 0.80
Epigenetic histone modifications and master regulators as determinants of context dependent nuclear receptor activity in bone cells. Bone (2015) 0.80
Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice. J Biol Chem (2016) 0.79
Role and mechanism of action of sclerostin in bone. Bone (2016) 0.78
Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann N Y Acad Sci (2015) 0.77
Osteocytic connexin 43 is not required for the increase in bone mass induced by intermittent PTH administration in male mice. J Musculoskelet Neuronal Interact (2016) 0.77
Simulated Interventions to Ameliorate Age-Related Bone Loss Indicate the Importance of Timing. Front Endocrinol (Lausanne) (2016) 0.75
Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging. Transgenic Res (2015) 0.75
Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75
Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry. J Bone Metab (2016) 0.75
Intraskeletal variation in human cortical osteocyte lacunar density: Implications for bone quality assessment. Bone Rep (2016) 0.75
Ex vivo replication of phenotypic functions of osteocytes through biomimetic 3D bone tissue construction. Bone (2017) 0.75
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
The amazing osteocyte. J Bone Miner Res (2011) 5.32
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest (2003) 3.60
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest (2001) 3.37
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem (2006) 3.04
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem (2003) 2.91
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res (2012) 2.53
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology (2005) 2.36
PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol (2010) 2.19
1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol (2005) 2.08
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol (2007) 1.86
Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res (2012) 1.81
Function of osteocytes in bone. J Cell Biochem (1994) 1.74
Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res (2007) 1.74
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res (2011) 1.72
Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res (2008) 1.70
Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One (2009) 1.67
Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord (2010) 1.64
Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet (2008) 1.63
Skeletal responses to space flight and the bed rest analog: a review. J Musculoskelet Neuronal Interact (2007) 1.62
Mineralized tissue cells are a principal source of FGF23. Bone (2007) 1.61
Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone (2011) 1.52
Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol (2011) 1.50
Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol (2006) 1.36
Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res (2011) 1.35
Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology (2003) 1.33
Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab (2010) 1.29
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab (2005) 1.26
PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res (1995) 1.23
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone (2010) 1.21
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol (2007) 1.19
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol (2010) 1.19
Cellular transformations in mammalian bones induced by parathyroid extract. Am J Anat (1950) 1.13
Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab (2008) 1.11
Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood (2012) 1.05
Role for parathyroid hormone in mechanical responsiveness of rat bone. Am J Physiol (1998) 1.03
Changes in the fine structure of bone cells after the administration of parathyroid extract. J Cell Biol (1967) 1.02
Osteocyte ultrastructure in renal osteodystrophy. Virchows Arch A Pathol Anat Histol (1977) 0.95
Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects. Bone (2011) 0.94
Ultrastructural changes in osteocytes in microgravity conditions. Adv Space Res (2002) 0.91
Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res (2007) 0.91
Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol (2000) 0.90
Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption. J Biol Chem (2007) 0.86
Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res (2012) 2.53
Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling. Blood (2012) 1.83
Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res (2012) 1.81
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Miner Res (2015) 1.60
Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol (2011) 1.50
Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem (2013) 1.23
Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging (2009) 0.90
The vitamin D receptor is required for activation of cWnt and hedgehog signaling in keratinocytes. Mol Endocrinol (2014) 0.83
Loss of Gsα early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors. J Bone Miner Res (2014) 0.83